|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We identified both known and novel somatic copy number aberrations (12p, MDM2, and RHBDD1) and mutations (XRCC2, PIK3CA, RITA1) including candidate markers for platinum resistance that were present in a primary tumor of mixed histology and that remained after tandem autologous stem cell transplant.
|
30870501 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RITA, the RBP-J interacting and tubulin-associated protein, has been reported to be related to tumor development, but the underlying mechanisms are not understood.
|
31353815 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo administration of RITA or GANT61 suppressed rhabdomyosarcoma xenograft growth in nude mice; however, co-administration did not further enhance tumor suppression, even though cell proliferation was decreased.
|
30447254 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
One such agent is RITA (reactivation of p53 and induction of tumor cell apoptosis), which restores p53 expression in cells with hyperactive HDM2 and induces apoptosis.
|
31699971 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.
|
28427187 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A recent study demonstrated that small-molecule RITA (reactivation of p53 and induction of tumor cell apoptosis) increased the radiosensitivity of tumor cells expressing mutant p53 (mtp53).
|
26134873 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Restoring normal p53 function has previously been investigated via the use of RITA (reactivation of p53 and induction of tumor cell apoptosis), a small molecule that induces a conformational change in p53, leading to activation of its downstream targets.
|
25119136 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results demonstrate that adjacent nontumoral liver samples exhibited increased RITA expression compared to HCC tissues (p < 0.05); RITA levels were associated with tumor differentiation status.
|
24308154 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We evaluated whether the restoration of p53 function by the p53-reactivating small molecule RITA (reactivation of p53 and induction of tumor cell apoptosis enhances cisplatin-induced cytotoxicity and apoptosis in head-and-neck cancer (HNC).
|
22634494 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have recently shown that induction of the p53 tumour suppressor protein by the small-molecule RITA (reactivation of p53 and induction of tumour cell apoptosis; 2,5-bis(5-hydroxymethyl-2-thienyl)furan) inhibits hypoxia-inducible factor-1α and vascular endothelial growth factor expression in vivo and induces p53-dependent tumour cell apoptosis in normoxia and hypoxia.
|
21593792 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Accordingly, treatment of certain wild-type p53-expressing tumor cell lines with the p53-reactivating small molecular compound RITA resulted in upregulation of ULBP2 mRNA and cell surface protein expression.
|
21764762 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, RITA is a promising lead for the development of anti-cancer drugs that reactivate the tumor suppressor function of p53 in cancer cells irrespective whether they express mutant or wild type p53.
|
20436301 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PRIMA-1 (p53-dependent reactivation and induction of massive apoptosis) restores the wild-type conformation of mutant TP53, whereas RITA (reactivation of p53 and induction of tumour cell apoptosis) increases intracellular levels of p53.
|
18341636 |
2008 |